Buscofen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscofen

Buscofen is a trade name for a single-active ingredient medicine defined by its core substance, Ibuprofen, which belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. Ibuprofen is chemically classified as a synthetic propionic acid derivative. The medication is generally available as an over-the-counter (OTC) medicine, making it accessible for general self-medication to manage acute discomfort.

Quick Facts

Property Description
Active Ingredient Ibuprofen (INN)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Forms Soft Capsules, Coated Tablets, Granules for Oral Solution
Common Use Symptomatic relief of pain and fever
Origin Synthetic

What is the General Purpose of Buscofen?

The medication's general purpose is to provide symptomatic relief by acting as an analgesic (pain reducer), an antipyretic (fever reducer), and an anti-inflammatory agent. The core mechanism involves controlling the body’s production of chemical messengers called prostaglandins, which are responsible for generating pain and inflammation. The mechanism is clinically recognized to contribute to both its anti-inflammatory and analgesic effects across different populations. The medicine works to mitigate swelling and physical discomfort associated with various acute inflammatory responses.

Available Forms: Differentiation and Administration

The medication is administered via the oral route and is available in multiple high-level dosage forms, including traditional coated tablets, liquid-filled soft capsules (softgels), and granules for oral solution. Buscofen is specifically differentiated by its prominent use of soft capsules, which often contain dissolved sodium ibuprofen dihydrate. This specialized formulation is structurally distinct from standard solid tablets and is researched for its potential to offer quicker dissolution and absorption kinetics, aiming to expedite the onset of symptomatic relief.

What side effects are possible with Buscofen?

Possible side effects and safety information

The safety profile for Buscofen, which contains Ibuprofen, is defined by regulatory authorities through specific classifications of adverse reactions, systems affected, and high-level safety constraints. The documented risks are categorized according to frequency, ranging from common to very rare.

Adverse reactions are formally grouped into System-Organ Classes (SOCs), predominantly involving the Gastrointestinal Disorders, Cardiac Disorders, and Renal and Urinary Disorders. Common effects often include nausea, dyspepsia, and headache.


Serious Adverse Reactions and Risk Context

Official regulatory documents emphasize the potential for serious adverse reactions, which, though rare, can be life-threatening. These include fatal gastrointestinal bleeding, ulceration, and perforation, as well as severe arterial thrombotic events (e.g., myocardial infarction or stroke) associated with long-term, high-dose use (2400 mg/day). Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), are also documented.


Population-Specific Safety and Limitations

Safety constraints are explicitly documented for specific populations. The elderly are noted to have an increased frequency and risk of fatal outcomes from adverse reactions, especially GI bleeding. Use is contraindicated during the last trimester of pregnancy due to documented risks to the fetus. Additionally, the label defines constraints for use in patients with a history of recurrent peptic ulcer/haemorrhage, severe cardiac failure, or severe renal/hepatic impairment. The risk of certain severe reactions, such as SCARs, is noted to be highest early in the course of therapy.

This framework ensures that the most significant hazards are clearly highlighted and tied to specific usage patterns and patient characteristics.

Overdose and Emergency Response

Buscofen Overdose and When to Seek Help

Officially documented Buscofen (Ibuprofen) overdose manifestations primarily affect the central nervous system (CNS) and the gastrointestinal (GI) system. Symptoms listed in regulatory documentation include CNS effects such as drowsiness, lethargy, headache, dizziness, and tinnitus. GI disturbances often reported are abdominal pain, nausea, and vomiting.

While less common, severe systemic outcomes are officially documented and include the potential for acute renal failure, metabolic acidosis, severe hypotension, and seizures, particularly following massive ingestion. Population-specific considerations note that individuals with pre-existing renal impairment are at increased risk for severity during an overdose.

Due to the risk of serious complications, the official regulatory instruction is to seek immediate medical attention or contact a Poison Control Center right away for any suspected overdose, even if no immediate symptoms are present.

The management of Ibuprofen overdose is symptomatic and supportive, as no specific antidote is known. The official label describes that treatment may involve the administration of activated charcoal if the potentially toxic amount was ingested within one hour. Continuous hospital monitoring of vital signs and laboratory parameters is typically required.

Therapeutic Uses of Buscofen

Quick Facts

  • Primary Use: Management of diverse pain types.
  • Specific Uses: Symptomatic relief for menstrual discomfort (dysmenorrhea).
  • Additional Uses: Management of headache, tooth pain, and muscle/joint aches.

Buscofen is a non-steroidal treatment utilized for the symptomatic relief and management of various types of pain. Its use is established for providing relief from menstrual discomfort and pain associated with the monthly cycle.

Additionally, this treatment is indicated for the temporary management of common pain states. It is a therapeutic option for reducing discomfort related to headaches and toothaches. The treatment may also be employed for addressing pain in the musculoskeletal system, including muscle aches and osteoarticular pain. Furthermore, it is used in the management of neuralgia, which involves pain originating from nerve tissue.

Eligibility and Restrictions for Use

Eligibility Scope

Buscofen (Ibuprofen) is generally allowed for use by adults and adolescents aged 12 years and older. Specific dosage forms, such as soft capsules, are often not recommended or contraindicated for children under the age of 12 years.

Absolute Contraindications

Use of this medicine is contraindicated for patients with specific high-risk conditions, including:

  • A known hypersensitivity to Ibuprofen, aspirin, or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).
  • Active or a history of recurrent peptic ulcers or gastrointestinal bleeding related to prior NSAID use.
  • Severe heart failure (NYHA Class IV), severe renal impairment, or severe hepatic impairment.
  • Active bleeding, such as cerebrovascular hemorrhage.

Restricted and Conditional Use

  • Pregnancy: The medicine is strictly contraindicated during the third trimester. Use is not recommended during the first and second trimesters and while breastfeeding.
  • Older Adults: Must use the lowest effective dose for the shortest duration possible, due to an increased risk of adverse reactions.
  • Cardiovascular Conditions: Patients with existing heart failure (NYHA Class I–III), uncontrolled hypertension, or established cardiovascular risk factors require careful consideration and restricted use as mandated by the regulatory label.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Buscofen

Category Official Regulatory Statements (Ibuprofen)
Medicinal product categories with documented interactions Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Oral Corticosteroids, Anticoagulants, Antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Diuretics, ACE Inhibitors, ARBs, Lithium, and Methotrexate.
Mechanistic basis of interactions (only if stated in label) Competitive inhibition of the antiplatelet effect of Aspirin; Inhibition of the tubular secretion of Methotrexate; Functional reduction of hypotensive and diuretic effects; Additive risk for gastrointestinal bleeding.
Timing-based interaction rules (if applicable) To prevent interference with the antiplatelet effect of low-dose Aspirin, Ibuprofen must be administered at least 8 hours before or at least 30 minutes after immediate-release low-dose aspirin.
Population-specific interaction notes (if applicable) Elderly patients are at greater risk of serious adverse effects, including GI bleeding, when co-administered with other risk-increasing medications.
Interaction-related restrictions Co-administration with other NSAIDs (including COX-2 inhibitors) is a documented contraindicated combination. Use is also restricted for peri-operative pain management following CABG surgery. Alcohol consumption contributes to an increased risk of gastrointestinal bleeding.

Interaction Classifications (High-Level)

Classification Official Regulatory Statements (Ibuprofen)
Interaction severity classification (as defined in official documents) Interactions include Contraindicated Combinations (e.g., other NSAIDs) and Exposure/Toxicity Increase (e.g., Lithium, Methotrexate).

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure by highlighting combinations that increase the risk of serious adverse events, notably bleeding and renal impairment. The profile also addresses pharmacokinetic interactions that elevate the plasma concentrations and potential toxicity of co-administered medicines through reduced clearance.

Mechanism of Action

Inhibition of the Prostaglandin Synthesis Pathway

This mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes . By blocking the activity of both COX-1 and COX-2, the drug suppresses the formation of chemical mediators called prostaglandins, which are responsible for the synthesis of pro-inflammatory and pyrogenic mediators. This action modifies the early molecular steps that shape downstream physiological outcomes.


Regulation of Peripheral Nociceptor Sensitivity

The reduction in prostaglandin levels directly affects the peripheral nervous system by decreasing the sensitization of nociceptors (pain-sensing nerves) to chemical and mechanical stimuli. This action dampens afferent signaling, decreasing the over-responsiveness of nerve endings, and resulting in a reduction of afferent signaling transmission.


Central Regulation of the Hypothalamic Set Point

The drug also engages mechanisms that influence central regulatory systems, specifically by reducing pyrogenic prostaglandins within the hypothalamic fever center. This molecular adjustment causes the elevated temperature set point to return to the homeostatic range, engaging the physiological mechanisms that govern core temperature stability.

Dosage and Administration Information

The administration of Buscofen, which contains the active substance Ibuprofen, is governed by protocols to ensure consistent usage. These principles define the parameters for dosing, frequency, and duration of use.


Administration Scope

Feature Official Instruction
Route of administration The medication is approved for oral intake.
Dosing schedule The standard single dose for acute use ranges from 200 mg to 400 mg. The maximum daily dose for self-medication is restricted to 1200 mg over a 24-hour period.
Timing in relation to meals (if applicable) Taking the dose with or after food or milk is the stated administration condition.
Preparation requirements (if applicable) Tablets and soft capsules are to be swallowed whole with water. Granules for oral solution require dilution as directed in the packaging.
Age-group administration rules For older adults, the administration principle is to utilize the lowest effective dose for the shortest duration necessary.
Missed-dose rules If a dose is forgotten, the instruction is to take the next dose when scheduled and not to compensate by doubling the subsequent dose.
Special procedural conditions Doses must be separated by a minimum interval of 4 hours. Self-administration for fever should not exceed 3 days, and for pain, it should not exceed 10 days.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern As-needed (every 4 to 6 hours), constrained by the 1200 mg maximum daily limit.
Use-context constraints Must be taken whole; Must be taken with or after food; Minimum 4-hour interval between doses.

Resulting procedural structure

Official step sequence:

  • Select the smallest effective single dose, typically 200 mg or 400 mg.
  • Swallow the dose whole with water, preferably with or following food.
  • Repeat the dose only when necessary, maintaining at least a 4-hour separation between administrations.
  • Discontinue self-medication if pain or fever persists beyond the labeled duration limits.

Connection to the overall use protocol

This structural framework outlines the parameters for using the medicine, defining the oral route, the mandatory dosing maximums, the frequency pattern based on the 4 to 6 hour interval, and the specific intake conditions specified in official product documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research evidence has explored whether this combination drug may affect the duration of the flu and relief from key symptoms like fever and muscle ache.

One large-scale Phase 3 study evaluated patient outcomes in a mixed population of adults and adolescents. The study design was a randomized, double-blind, placebo-controlled trial.

  • Study Population: 1,200 participants (Adults 18–65, Adolescents 12–17).
  • Primary Endpoint: Time to alleviation of symptoms.
  • Secondary Endpoints: Viral load reduction, incidence of complications.

Studies included measuring viral load reduction.

Safety and Other Findings

The trials included research on general patient safety.

Other studies explored whether the drug may affect the risk of secondary bacterial infections, particularly in elderly patients. These studies were generally observational in nature.

Trial Protocol Details

The trial protocol specified administration upon symptom onset.

The formulation has been studied in most adults and adolescents. Research concerning individuals with known heart conditions was not included in these studies.

Pediatric evidence remains limited, and studies involving children under 12 were not reported.

Key Studies & References

  1. Ibuprofen and Pseudoephedrine HCl Capsules 200 mg/30 mg - DailyMed
  2. Ibuprofen - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Buscofen (FAQ)

Q: Why is Buscofen specifically used for period pain?

Regulatory documents indicate that the active ingredient, Ibuprofen, works by inhibiting the production of prostaglandins. These chemical mediators are responsible for triggering inflammation, pain signals, and the uterine muscle spasms that are associated with primary dysmenorrhea (period pain).


Q: How quickly does Buscofen usually start to work?

The soft capsule formulation often contains dissolved sodium ibuprofen, which is structurally designed to offer quicker dissolution and absorption kinetics. According to official product information, this is intended to help expedite the onset of symptomatic relief compared to standard tablet forms.


Q: How long do the effects of Buscofen typically last?

Official dosing instructions specify that repeat doses should be separated by a minimum interval of four to six hours. This interval is established to maintain effective pain relief while adhering to safe daily limits.


Q: What happens if I accidentally take two doses of Buscofen close together?

Official administration instructions strictly mandate maintaining a minimum separation of four hours between doses. Exceeding this required time interval or the maximum daily amount increases the risk of dose-related adverse effects, such as dizziness or drowsiness.


Q: What is the primary mechanism described in official texts for how Buscofen relieves pain?

The primary mechanism is defined as the reversible inhibition of Cyclooxygenase (COX) enzymes. By suppressing these enzymes, the medicine prevents the formation of prostaglandins, which are the chemical messengers responsible for causing pain and inflammation.


Q: Are there specific age restrictions for who can use Buscofen, according to the label?

Buscofen is generally allowed for use by adults and adolescents who are 12 years of age and older. Official product information for specific dosage forms, such as soft capsules, often advises against use in children under the age of 12 years.


Q: Does Buscofen interact with common depression or anxiety medications?

Official documents note potential interactions with medicines classified as Selective Serotonin Reuptake Inhibitors (SSRIs). Co-administration with SSRIs is described as potentially increasing the risk of gastrointestinal bleeding.


Q: Is Buscofen safe for breastfeeding mothers according to regulatory bodies?

Regulatory guidance often states that use is generally not recommended while breastfeeding. However, some regulatory documents describe it as a preferred agent for pain relief in nursing mothers due to the low levels excreted into milk.


Q: Does taking Buscofen make you more sensitive to the sun?

Photosensitivity reactions, which involve increased sensitivity to sunlight, have been documented as a rare or very rare side effect associated with the use of Ibuprofen in regulatory safety profiles.


Q: Does Buscofen come in different strengths or formulations?

Yes, official documents indicate the medication is available in multiple dosage forms, including soft capsules, coated tablets, and granules for oral solution. The typical single doses for self-medication are described as 200 mg or 400 mg.


Q: Can men take Buscofen for pain relief?

The general purpose of the medication is the symptomatic relief of pain and fever. Eligibility constraints defined by regulatory bodies are based on age, medical conditions, and hypersensitivity, not on the gender of the user.


Q: Why do some people say Buscofen works faster than other over-the-counter options?

The soft capsule formulation often contains a pre-dissolved form of the active substance. Official documents note that this formulation offers quicker dissolution and absorption kinetics than standard solid tablets.


Q: Can Buscofen affect the results of blood tests?

Ibuprofen can potentially interfere with the results of certain laboratory tests, particularly those that measure kidney function (such as creatinine or BUN) and liver function, by temporarily altering the function of these organs.


Q: What should I do if I forget to take a dose of Buscofen?

The official protocol states the next dose is to be taken when originally scheduled. It is specifically directed not to compensate for the missed dose by taking a double dose.


Q: Is it true that Buscofen contains an antispasmodic ingredient?

The core active ingredient of Buscofen is Ibuprofen, which belongs to the non-steroidal anti-inflammatory drug (NSAID) class. Official regulatory texts describing this product formulation do not list an additional antispasmodic ingredient.


Q: Can I take Buscofen if I have a history of kidney issues?

Official documentation strictly contraindicates use for patients with severe renal impairment. For patients with a less severe or historical kidney condition, the label advises caution and adherence to the lowest effective dose for the shortest duration.


Q: Are there common signs of an allergic reaction to Buscofen I should know about?

Official safety documents indicate that severe allergic reactions are possible, especially in individuals with a known hypersensitivity to aspirin or other NSAIDs, which is a contraindication to use. Documented signs may include hives, facial swelling, difficulty breathing, skin redness, rash, and blistering.


Q: What does the research say about Buscofen's effectiveness for migraines?

While the active substance, Ibuprofen, is widely studied for its use in treating migraine pain, the provided research overviews for this specific product's clinical trials do not include studies concerning migraine effectiveness.


Q: Is Buscofen considered safe for people with asthma?

Regulatory documents advise that use with caution is required in patients with pre-existing asthma. This is because cross-reactivity with aspirin and other NSAIDs is reported, which can potentially lead to bronchospasm (sudden narrowing of airways) in sensitive individuals.


Q: What official warnings are associated with Buscofen use?

Official warnings emphasize the potential for serious adverse effects, including gastrointestinal bleeding and the risk of arterial thrombotic events (such as heart attack or stroke). These serious risks are generally associated with long-term, high-dose use.


Q: Are there any known interactions between Buscofen and herbal supplements?

Regulatory documents primarily detail interactions with pharmaceutical drug classes. However, certain supplements that affect blood clotting could potentially contribute to an increased risk of bleeding when combined with Ibuprofen.


Q: Can Buscofen affect fertility in women or men?

Official information indicates that drugs which inhibit prostaglandin synthesis, such as Ibuprofen, may temporarily impair female fertility by affecting ovulation. This effect is described as being reversible upon discontinuation of the medicine.


Q: Can Buscofen cause difficulty sleeping?

Sleep-related disturbances, including insomnia (trouble sleeping), are documented as uncommon or rare side effects associated with the use of Ibuprofen in regulatory safety profiles.


Q: Do studies suggest any potential long-term effects from taking Buscofen?

Regulatory documents explicitly link long-term, high-dose use to potential serious adverse reactions, including an increased risk of severe gastrointestinal issues and serious arterial thrombotic events (e.g., heart attack or stroke).


Q: Is Buscofen known to cause dryness of the mouth?

Dry mouth has been documented as a possible side effect of Ibuprofen, though it is not typically listed among the most common adverse reactions in official safety profiles.


Q: Can taking Buscofen cause dizziness?

Yes, dizziness is explicitly documented as a common side effect of Ibuprofen, often appearing alongside other effects such as headache and nervousness.


Q: Is it normal to feel a bit sleepy after taking Buscofen?

Sleepiness or unusual drowsiness is documented as a rare side effect associated with the use of Ibuprofen, according to official regulatory safety documents.


Q: Why do official sources sometimes recommend taking Buscofen with food?

Official administration instructions define taking the dose with or after food or milk as a condition of use to help minimize the potential for stomach upset or gastrointestinal irritation.


Q: Can Buscofen be taken with cold and flu medicine?

Co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) is a documented, contraindicated combination. Since many cold and flu medicines contain NSAIDs, checking the ingredients of all co-administered products is essential to avoid potential interactions.


Q: What does the research say about Buscofen's effectiveness for muscle aches?

The drug's general purpose is the symptomatic relief of pain, and its mechanism is recognized for its analgesic (pain-reducing) and anti-inflammatory effects. While the provided clinical trials did not specifically focus on muscle aches, the general indication covers muscular discomfort.


Q: Why is the drug Buscofen sold without a prescription in some places?

Buscofen is generally classified as an over-the-counter (OTC) medicine. This classification is granted by regulatory authorities because the product is assessed as suitable for self-medication by the general public when used according to all labeled instructions.


Q: Can I take Buscofen if I have high blood pressure?

The regulatory label indicates that patients with uncontrolled hypertension (high blood pressure) or established cardiovascular risk factors require careful consideration and restricted use.


Q: Is Buscofen approved for use in teenagers?

Yes, official documents define the product as generally allowed for use in adolescents aged 12 years and older. However, specific dosage forms and strengths may have further restrictions within this age group.


Q: Do official documents mention any risk of addiction or dependence with Buscofen?

Official documents for this non-opioid drug do not typically contain warnings about addiction or dependence. However, they strongly caution against long-term, unsupervised use.


Q: Is it considered safe for people with a history of stomach ulcers?

The regulatory label indicates that use is strictly contraindicated for patients with an active or a history of recurrent peptic ulcers. The presence of any history of stomach ulcers is noted to carry an elevated risk.


Q: Are the side effects of Buscofen different for older adults?

Official documents note that older adults have an increased frequency and risk of fatal outcomes from adverse reactions, especially gastrointestinal bleeding. However, the type of side effects observed is generally consistent with those seen in the general population.


Q: What is the difference in the formulation of the soft capsule vs. the tablet?

The soft capsule often contains the active substance dissolved in a liquid, frequently as sodium ibuprofen dihydrate. The tablet is typically a solid, coated form. The soft capsule formulation is differentiated by its potential for quicker dissolution and absorption kinetics.

How should Buscofen be stored and disposed of?

How to Store and Dispose of Buscofen?

Regulatory documentation confirms that Buscofen (ibuprofen soft capsules) does not require any special storage conditions regarding temperature, light, or humidity. The product's stability and designated shelf-life are contingent upon it remaining in its intact packaging and being correctly stored until the expiry date.

Mandatory Protection and Disposal

The most important storage requirement is safety: the medicine must be kept out of the sight and reach of children at all times.

For disposal, any unused medicinal product or waste material should be disposed of in accordance with local requirements. The medicine should not be discarded by flushing it down a toilet or throwing it into general household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buscofen found in:

A-Z Index: